Quetiapine in patients with schizophrenia: A high- and low-dose double- blind comparison with placebo

Archives of General Psychiatry

Volumn 54, Issue 6, 1997, Pages 549-557

  Small, Joyce G ^a   Hirsch, Steven R ^b   Arvanitis, Lisa A ^c,d   Miller, Barbara G ^c   Link, Christopher G G ^c  

^a Larue D Carter Memorial Hospital   (United States)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d CNS Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PLACEBO; QUETIAPINE;

ADULT; AGITATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGATIVE SYNDROME; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TREATMENT OUTCOME;

EID: 0030920294     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1997.01830180067009     Document Type: Article

References (20)

1. Peroutka SJ, Snyder SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry. 1980;137:1518-1522.
2. Kane JM, Freeman HL. Towards more effective antipsychotic treatment. Br J Psychiatry. 1994;165:22-31.
3. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology. 1993;112:285-292.
4. Goldstein JM. Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Expert Opinion Invest Drugs. 1995;4:291-298.
5. Migler BM, Litwin LC, Sutton EB, Malick JB. Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology. 1993;112:293-307.
6. Carey G, Bergman J. Discriminative stimulus effects of proposed atypical antipsychotics in clozapine-trained squirrel monkeys. Behav Pharmacol. 1994;5 (suppl 1):114.
7. Ellenbroek BA, Lubbers LJ, Cools AR. The activity of 'Seroquel' (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Neuropsychopharmacology. In press.
8. Fabre LF, Arvanitis LA, Pultz J, Jones VM, Malick JB, Slotnick VB. ICI 204,636, a novel atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther. 1995;17:366-378.
9. Borison RL, Arvanitis LA, Miller BG, and the US Seroquel Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol. 1996; 16:158-169.
10. Goldstein JM, Arvanitis LA. ICI 204,636 (Seroquel): a dibenzothiazepine atypical antipsychotic: review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Rev. 1995;1:50-73.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
12. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962; 10:799-812.
13. CGI Clinical Global Impressions: ECDEU Assessment Manual for Psychopharmacology (Revised Edition). Rockville, Md: US Dept of Health, Education, and Welfare; 1976:218-222.
14. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;212:11-19.
15. Andreasen N. Modified Scale for the Assessment of Negative Symptoms. Rockville, Md: Dept of Health and Human Services, Public Health Administration; 1984. National Institutes of Mental Health publication ADM 9-102.
16. Kay SR, Opler LA, Lindenmayer J-P. The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry. 1989;155:59-65.
17. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989; 154:672-676.
18. AIMS: ECDEU Assessment Manual for Psychopharmacology (Revised Edition). Rockville, Md: US Dept of Health, Education, and Welfare; 1976:534-535. US Dept of Health, Education, and Welfare publication ADM 76-338.
19. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835.
20. Chouinard G, Jones B, Remington G, Bloom D, Addington O, MacEwan GW, Labelle A, Beuclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of riperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25-40.